Danielle Hammond

Targeted therapy with the mutant <i>IDH2</i> inhibitor enasidenib for high-risk <i>IDH2</i>-mutant myelodysplastic syndrome

Courtney D. DiNardo, Sangeetha Venugopal, Curtis A. Lachowiez et al. · Blood Advances · 2022 · 64 citations · Full text

Medicine, Oncology, Pharmacology +14

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Jayastu Senapati, Samuel Urrutia, Sanam Loghavi et al. · Blood · 2023 · 61 citations

Medicine, Genetics, Oncology +13

Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia

Chong Chyn Chua, Danielle Hammond, Andrew Kent et al. · Blood Advances · 2022 · 60 citations · Full text

Medicine, Oncology, Pharmacology +16

Cost utility of behavioural activation delivered by the non-specialist

David Ekers, Christine Godfrey, Simon Gilbody et al. · The British Journal of Psychiatry · 2011 · 58 citations · Full text

Pharmacy, Pharmacoeconomics, Behavioral Health +14

Characteristics and clinical outcomes of patients with myeloid malignancies and <scp><i>DDX41</i></scp> variants

Álex Bataller, Sanam Loghavi, Yoheved Gerstein et al. · American Journal of Hematology · 2023 · 46 citations · Full text

Life Sciences, Genetics, Hematology +16